Intracellular genomic transplant and methods of therapy
AssigneesIntima Bioscience, Inc., Regents of the University of Minnesota, The United States of America, as represented by the Secretary, Department of Health and Human Services
InventorsBranden Moriarity, Beau Webber, Modassir Choudhry, Steven A. Rosenberg, Douglas C. Palmer, Nicholas P. Restifo
Life of this patent
Estimating the term…
Abstract
Genetically modified compositions, such as non-viral vectors and T cells, for treating cancer are disclosed. Also disclosed are the methods of making and using the genetically modified compositions in treating cancer.
Claims17
A pharmaceutical composition that comprises an ex vivo engineered human primary immune cell that comprises:
- a) a genomic disruption within a cytokine inducible SH2-containing protein gene target sequence that comprises any one of SEQ ID NO:
- 75— SEQ ID NO:
- 86, wherein said genomic disruption comprises an endonuclease-mediated indel;
- and
- b) at least one nucleic acid encoding an exogenous functional T cell receptor, or a functional fragment thereof, or an exogenous functional chimeric antigen receptor, or a functional fragment thereof,
- wherein said exogenous functional T cell receptor, or said functional fragment thereof, or said exogenous functional chimeric antigen receptor, or said functional fragment thereof, binds a neo-antigen expressed by a cancer cell, and wherein said neoantigen arises from a somatic mutation.
A pharmaceutical composition that comprises an ex vivo engineered human primary immune cell that comprises:
- a) a genomic disruption within a cytokine inducible SH2-containing protein gene target sequence that comprises any one of SEQ ID NO:
- 75— SEQ ID NO:
- 86, wherein said genomic disruption comprises an endonuclease-mediated indel;
- and
- b) at least one nucleic acid encoding an exogenous functional T cell receptor, or a functional fragment thereof, or an exogenous functional chimeric antigen receptor, or a functional fragment thereof,
- wherein said exogenous functional T cell receptor, or said functional fragment thereof, or said exogenous functional chimeric antigen receptor, or said functional fragment thereof, binds a neo-antigen expressed by a breast cancer cell.
Dependencies are inferred from the claim text.